Clinical Trials
2 trialsNCT03195699 2025-03-21
Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers
Tvardi Therapeutics, Incorporated
Phase 1 Completed
NCT05384119 2025-02-21
Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer
Tvardi Therapeutics, Incorporated
Phase 1 Terminated